arrow_back Back to App

Improved Access to Rare Disease Drugs: New Pricing Rules.

This act aims to improve access to drugs for rare diseases by changing how they are considered in the drug price negotiation program. This could encourage pharmaceutical companies to develop more treatments for conditions affecting a small number of people, potentially leading to more treatment options for patients with rare diseases.
Key points
Drugs for rare diseases (orphan drugs) will have modified rules for price negotiations, potentially affecting their availability.
The act clarifies that drugs for one or more rare diseases will be treated specially to support their development.
The period a drug was designated for a rare disease will not count towards the time after which it becomes subject to price negotiations, giving companies more time to recoup research costs.
article Official text account_balance Process page
Introduced
Citizen Poll
No votes cast
Additional Information
Print number: 119_S_1862
Sponsor: Sen. Barrasso, John [R-WY]
Process start date: 2025-05-22
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

ORPHAN Cures Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 119_S_1862.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2025-05-22.

What are the main provisions?

Key points include:

  • Drugs for rare diseases (orphan drugs) will have modified rules for price negotiations, potentially affecting their availability.
  • The act clarifies that drugs for one or more rare diseases will be treated specially to support their development.
  • The period a drug was designated for a rare disease will not count towards the time after which it becomes subject to price negotiations, giving companies more time to recoup research costs.
What is the specific legal status?

The current status is Introduced.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Barrasso, John [R-WY].

What is the latest detailed status?

The latest detailed status is: Introduced in Senate

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-23.

CATEGORIES

Health